{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:07:39Z","timestamp":1790158059168,"version":"4.1.0"},"reference-count":130,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.3892\/mmr.2017.7179","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T09:45:25Z","timestamp":1502099125000},"page":"4393-4402","source":"Crossref","is-referenced-by-count":64,"title":["Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions"],"prefix":"10.3892","volume":"16","author":[{"given":"Nunzia","family":"Caporarello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cristaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Cambria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Salmeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelina Daniela","family":"Anfuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,8,7]]},"reference":[{"key":"key20180108003410_b1-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"key20180108003410_b2-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/cam4.105","article-title":"Vessel co-option in primary human tumors and metastases: An obstacle to effective anti-angiogenic treatment?","volume":"2","author":"Donnem","year":"2013","journal-title":"Cancer Med"},{"key":"key20180108003410_b3-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"key20180108003410_b4-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nrc2791","article-title":"Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors","volume":"10","author":"Butler","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20180108003410_b5-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"key20180108003410_b6-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"key20180108003410_b7-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1073\/pnas.94.3.861","article-title":"Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways","volume":"94","author":"Arbiser","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108003410_b8-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.7521539","article-title":"Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1","volume":"265","author":"Dameron","year":"1994","journal-title":"Science"},{"key":"key20180108003410_b9-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"key20180108003410_b10-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"key20180108003410_b11-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","article-title":"Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor","volume":"92","author":"Soker","year":"1998","journal-title":"Cell"},{"key":"key20180108003410_b12-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling - in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180108003410_b13-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.1079562","article-title":"Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1","volume":"299","author":"LeCouter","year":"2003","journal-title":"Science"},{"key":"key20180108003410_b14-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1073\/pnas.1109029108","article-title":"Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy","volume":"108","author":"Yao","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108003410_b15-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/ijms14010088","article-title":"The role of the VEGF-C\/VEGFRs axis in tumor progression and therapy","volume":"14","author":"Chen","year":"2012","journal-title":"Int J Mol Sci"},{"key":"key20180108003410_b16-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1161\/ATVBAHA.111.225961","article-title":"Vascular endothelial growth factor (VEGF)-D stimulates VEGF-A, stanniocalcin-1, and neuropilin-2 and has potent angiogenic effects","volume":"31","author":"Jauhiainen","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20180108003410_b17-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108003410_b18-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1073\/pnas.0503168102","article-title":"Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo","volume":"102","author":"Jendreyko","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108003410_b19-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.01.010","article-title":"VEGF\/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-\u03baB and \u03b2-catenin","volume":"373","author":"Luo","year":"2016","journal-title":"Cancer Lett"},{"key":"key20180108003410_b20-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"a006502","DOI":"10.1101\/cshperspect.a006502","article-title":"Signal transduction by vascular endothelial growth factor receptors","volume":"2","author":"Koch","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"key20180108003410_b21-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/ATVBAHA.114.303215","article-title":"Canonical and noncanonical vascular endothelial growth factor pathways: New developments in biology and signal transduction","volume":"35","author":"Domigan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20180108003410_b22-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni1013","article-title":"Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins","volume":"5","author":"Karkkainen","year":"2004","journal-title":"Nat Immunol"},{"key":"key20180108003410_b23-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1128\/MCB.25.6.2441-2449.2005","article-title":"Vascular endothelial growth factor D is dispensable for development of the lymphatic system","volume":"25","author":"Baldwin","year":"2005","journal-title":"Mol Cell Biol"},{"key":"key20180108003410_b24-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1128\/MCB.02214-07","article-title":"Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos","volume":"28","author":"Haiko","year":"2008","journal-title":"Mol Cell Biol"},{"key":"key20180108003410_b25-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/01.RES.77.3.638","article-title":"Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5 enhancer","volume":"77","author":"Liu","year":"1995","journal-title":"Circ Res"},{"key":"key20180108003410_b26-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.33549\/physiolres.932789","article-title":"HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors","volume":"63","author":"Jochmanov\u00e1","year":"2014","journal-title":"Physiol Res"},{"key":"key20180108003410_b27-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"key20180108003410_b28-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180108003410_b29-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180108003410_b30-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180108003410_b31-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180108003410_b32-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20180108003410_b33-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Bevacizumab for advanced cervical cancer: Patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"key20180108003410_b34-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bcp.2015.05.017","article-title":"Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2\/COX-2\/VEGF-A pathway","volume":"96","author":"Giurdanella","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"key20180108003410_b35-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11912-013-0368-7","article-title":"Aflibercept - a decoy VEGF receptor","volume":"16","author":"Ciombor","year":"2014","journal-title":"Curr Oncol Rep"},{"key":"key20180108003410_b36-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"key20180108003410_b37-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180108003410_b38-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"key20180108003410_b39-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11912-011-0154-3","article-title":"Development of second-generation VEGFR tyrosine kinase inhibitors: Current status","volume":"13","author":"Bhargava","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"key20180108003410_b40-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"key20180108003410_b41-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180108003410_b42-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180108003410_b43-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"587259","DOI":"10.5402\/2012\/587259","article-title":"Molecular biomarkers of response to antiangiogenic therapy for cancer","volume":"2012","author":"Duda","year":"2012","journal-title":"ISRN Cell Biol"},{"key":"key20180108003410_b44-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180108003410_b45-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.critrevonc.2013.08.012","article-title":"Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma","volume":"89","author":"Ranieri","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180108003410_b46-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"RAINBOW Study Group: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20180108003410_b47-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"key20180108003410_b48-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"REGARD Trial Investigators: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"key20180108003410_b49-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"RAISE Study Investigators: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20180108003410_b50-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2014.57.1513","article-title":"Primary results of ROSE-TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","volume":"33","author":"Mackey","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20180108003410_b51-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"REACH Trial Investigators: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20180108003410_b52-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1517\/14712598.2015.1071350","article-title":"The coming of ramucirumab in the landscape of anti-angiogenic drugs: Potential clinical and translational perspectives","volume":"15","author":"Calvetti","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"key20180108003410_b53-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2045-824X-3-20","article-title":"Dll4-Notch signaling as a therapeutic target in tumor angiogenesis","volume":"3","author":"Kuhnert","year":"2011","journal-title":"Vasc Cell"},{"key":"key20180108003410_b54-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/01.ATV.0000060892.81529.8F","article-title":"Notch signaling in vascular development","volume":"23","author":"Iso","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20180108003410_b55-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature05571","article-title":"Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis","volume":"445","author":"Hellstr\u00f6m","year":"2007","journal-title":"Nature"},{"key":"key20180108003410_b56-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1158\/0008-5472.CAN-05-1208","article-title":"Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function","volume":"65","author":"Patel","year":"2005","journal-title":"Cancer Res"},{"key":"key20180108003410_b57-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1432-0436.2001.690207.x","article-title":"Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis","volume":"69","author":"Mailhos","year":"2001","journal-title":"Differentiation"},{"key":"key20180108003410_b58-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nature05313","article-title":"Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis","volume":"444","author":"Ridgway","year":"2006","journal-title":"Nature"},{"key":"key20180108003410_b59-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nature05355","article-title":"Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis","volume":"444","author":"Noguera-Troise","year":"2006","journal-title":"Nature"},{"key":"key20180108003410_b60-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1182\/blood-2006-12-063933","article-title":"Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion","volume":"109","author":"Scehnet","year":"2007","journal-title":"Blood"},{"key":"key20180108003410_b61-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1158\/0008-5472.CAN-07-6499","article-title":"A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis","volume":"68","author":"Funahashi","year":"2008","journal-title":"Cancer Res"},{"key":"key20180108003410_b62-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2159-8290.CD-14-0650","article-title":"NOTCH decoys that selectively block DLL\/NOTCH or JAG\/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth","volume":"5","author":"Kangsamaksin","year":"2015","journal-title":"Cancer Discov"},{"key":"key20180108003410_b63-mmr-16-04-4393","first-page":"943","article-title":"Gamma secretase inhibitors of Notch signaling","volume":"6","author":"Olsauskas-Kuprys","year":"2013","journal-title":"Onco Targets Ther"},{"key":"key20180108003410_b64-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system","volume":"10","author":"Augustin","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180108003410_b65-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/74725","article-title":"Angiopoietin-1 protects the adult vasculature against plasma leakage","volume":"6","author":"Thurston","year":"2000","journal-title":"Nat Med"},{"key":"key20180108003410_b66-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.1618","article-title":"Angiopoietins in tumours: The angiogenic switch","volume":"204","author":"Tait","year":"2004","journal-title":"J Pathol"},{"key":"key20180108003410_b67-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1242\/jcs.01653","article-title":"The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism","volume":"118","author":"Scharpfenecker","year":"2005","journal-title":"J Cell Sci"},{"key":"key20180108003410_b68-mmr-16-04-4393","first-page":"1321","article-title":"MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models","volume":"40","author":"Leow","year":"2012","journal-title":"Int J Oncol"},{"key":"key20180108003410_b69-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/0008-5472.CAN-12-2064","article-title":"Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition","volume":"73","author":"Daly","year":"2013","journal-title":"Cancer Res"},{"key":"key20180108003410_b70-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1158\/1078-0432.CCR-13-0081","article-title":"Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy","volume":"19","author":"Kienast","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20180108003410_b71-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2004.09.030","article-title":"Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2","volume":"6","author":"Oliner","year":"2004","journal-title":"Cancer Cell"},{"key":"key20180108003410_b72-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20180108003410_b73-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"33205","DOI":"10.1074\/jbc.M113.510578","article-title":"Directed evolution of an angiopoietin-2 ligand trap by somatic hypermutation and cell surface display","volume":"288","author":"Brindle","year":"2013","journal-title":"J Biol Chem"},{"key":"key20180108003410_b74-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ctrv.2010.01.003","article-title":"Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma","volume":"36","author":"Schmidinger","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"key20180108003410_b75-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key20180108003410_b76-mmr-16-04-4393","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"key":"key20180108003410_b77-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.mvr.2009.09.001","article-title":"PKC\u03b1-MAPK\/ERK-phospholipase A2 signaling is required for human melanoma-enhanced brain endothelial cell proliferation and motility","volume":"78","author":"Anfuso","year":"2009","journal-title":"Microvasc Res"},{"key":"key20180108003410_b78-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbalip.2008.07.007","article-title":"Expression of Ca2+-independent and Ca2+-dependent phospholipases A2 and cyclooxygenases in human melanocytes and malignant melanoma cell lines","volume":"1781","author":"Scuderi","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"key20180108003410_b79-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbalip.2007.01.014","article-title":"Activation of cytosolic phospholipase A2 and 15-lipoxygenase by oxidized low-density lipoproteins in cultured human lung fibroblasts","volume":"1771","author":"Lupo","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"key20180108003410_b80-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"16959","DOI":"10.1074\/jbc.M701214200","article-title":"Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo","volume":"282","author":"Rao","year":"2007","journal-title":"J Biol Chem"},{"key":"key20180108003410_b81-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1006\/bbrc.2001.5494","article-title":"PGE2 stimulates VEGF expression in endothelial cells via ERK2\/JNK1 signaling pathways","volume":"286","author":"Pai","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180108003410_b82-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.canlet.2014.08.004","article-title":"An in vitro retinoblastoma human triple culture model of angiogenesis: A modulatory effect of TGF-\u03b2","volume":"354","author":"Lupo","year":"2014","journal-title":"Cancer Lett"},{"key":"key20180108003410_b83-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.biochi.2013.11.013","article-title":"Endothelial PKC\u03b1-MAPK\/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes?","volume":"99","author":"Anfuso","year":"2014","journal-title":"Biochimie"},{"key":"key20180108003410_b84-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1172\/JCI58976","article-title":"Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice","volume":"122","author":"Maione","year":"2012","journal-title":"J Clin Invest"},{"key":"key20180108003410_b85-mmr-16-04-4393","first-page":"5405","article-title":"Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)\/neu-induced breast cancer","volume":"62","author":"Howe","year":"2002","journal-title":"Cancer Res"},{"issue":"6B","key":"key20180108003410_b86-mmr-16-04-4393","first-page":"4245","article-title":"COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer","volume":"26","author":"Yoshinaka","year":"2006","journal-title":"Anticancer Res"},{"key":"key20180108003410_b87-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bjc.6600462","article-title":"Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer","volume":"87","author":"Connolly","year":"2002","journal-title":"Br J Cancer"},{"key":"key20180108003410_b88-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.18632\/oncotarget.3437","article-title":"Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs","volume":"6","author":"Ben-Batalla","year":"2015","journal-title":"Oncotarget"},{"key":"key20180108003410_b89-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"878450","DOI":"10.1155\/2014\/878450","article-title":"MicroRNAs: Promising new antiangiogenic targets in cancer","volume":"2014","author":"Gallach","year":"2014","journal-title":"BioMed Res Int"},{"key":"key20180108003410_b90-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/nar\/gkl183","article-title":"Improved targeting of miRNA with antisense oligonucleotides","volume":"34","author":"Davis","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"key20180108003410_b91-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in non-human primates","volume":"452","author":"Elm\u00e9n","year":"2008","journal-title":"Nature"},{"key":"key20180108003410_b92-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","article-title":"miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting","volume":"3","author":"Esau","year":"2006","journal-title":"Cell Metab"},{"key":"key20180108003410_b93-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with \u2018antagomirs\u2019","volume":"438","author":"Kr\u00fctzfeldt","year":"2005","journal-title":"Nature"},{"key":"key20180108003410_b94-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"14082","DOI":"10.1073\/pnas.0804597105","article-title":"Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis","volume":"105","author":"Su\u00e1rez","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108003410_b95-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ejca.2007.04.002","article-title":"The role of microRNAs in cancer: No small matter","volume":"43","author":"Wiemer","year":"2007","journal-title":"Eur J Cancer"},{"key":"key20180108003410_b96-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.devcel.2008.07.008","article-title":"miR-126 regulates angiogenic signaling and vascular integrity","volume":"15","author":"Fish","year":"2008","journal-title":"Dev Cell"},{"key":"key20180108003410_b97-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.devcel.2008.07.002","article-title":"The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis","volume":"15","author":"Wang","year":"2008","journal-title":"Dev Cell"},{"key":"key20180108003410_b98-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nbt1101","article-title":"Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors","volume":"23","author":"Song","year":"2005","journal-title":"Nat Biotechnol"},{"key":"key20180108003410_b99-mmr-16-04-4393","first-page":"3","article-title":"Extracellular matrix degradation and remodeling in development and disease","volume":"1","author":"Lu","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20180108003410_b100-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.drudis.2014.09.026","article-title":"Computational systems biology approaches to anti-angiogenic cancer therapeutics","volume":"20","author":"Finley","year":"2015","journal-title":"Drug Discov Today"},{"key":"key20180108003410_b101-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0197-2456(01)00153-2","article-title":"Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health workshop","volume":"22","author":"De Gruttola","year":"2001","journal-title":"Control Clin Trials"},{"key":"key20180108003410_b102-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ejca.2008.03.006","article-title":"Prognostic versus predictive value of biomarkers in oncology","volume":"44","author":"Oldenhuis","year":"2008","journal-title":"Eur J Cancer"},{"key":"key20180108003410_b103-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key20180108003410_b104-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180108003410_b105-mmr-16-04-4393","first-page":"1111","article-title":"Update on biomarkers in development of anti-angiogenic drugs in gastric cancer","volume":"36","author":"Jia","year":"2016","journal-title":"Anticancer Res"},{"key":"key20180108003410_b106-mmr-16-04-4393","first-page":"3193","article-title":"Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer","volume":"8","author":"Cooper","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20180108003410_b107-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.clinbiochem.2004.01.014","article-title":"Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients","volume":"37","author":"Kassim","year":"2004","journal-title":"Clin Biochem"},{"issue":"3b","key":"key20180108003410_b108-mmr-16-04-4393","first-page":"1973","article-title":"Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer","volume":"24","author":"Li","year":"2004","journal-title":"Anticancer Res"},{"key":"key20180108003410_b109-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2014.08.033","article-title":"The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer","volume":"135","author":"Secord","year":"2014","journal-title":"Gynecol Oncol"},{"key":"key20180108003410_b110-mmr-16-04-4393","first-page":"13","article-title":"Biomarkers of angiogenesis in colorectal cancer","volume":"7","author":"Mousa","year":"2015","journal-title":"Biomark Cancer"},{"key":"key20180108003410_b111-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"12444","DOI":"10.1039\/C5NR07887C","article-title":"Therapeutic application of anti-angiogenic nanomaterials in cancers","volume":"8","author":"Mukherjee","year":"2016","journal-title":"Nanoscale"},{"key":"key20180108003410_b112-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1021\/acsnano.5b01872","article-title":"MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: Nanoclinic in the brain","volume":"9","author":"Patil","year":"2015","journal-title":"ACS Nano"},{"key":"key20180108003410_b113-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nnano.2012.237","article-title":"Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface","volume":"8","author":"Salvati","year":"2013","journal-title":"Nat Nanotechnol"},{"key":"key20180108003410_b114-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/138920012798356899","article-title":"The ligand nanoparticle conjugation approach for targeted cancer therapy (Review)","volume":"13","author":"Karra","year":"2012","journal-title":"Curr Drug Metab"},{"key":"key20180108003410_b115-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3892\/ijo.2014.2706","article-title":"Nanoparticle strategies for cancer therapeutics: Nucleic acids, polyamines, bovine serum amine oxidase and iron oxide nanoparticles (Review)","volume":"46","author":"Agostinelli","year":"2015","journal-title":"Int J Oncol"},{"key":"key20180108003410_b116-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00726-009-0431-8","article-title":"Potential anticancer application of polyamine oxidation products formed by amine oxidase: A new therapeutic approach","volume":"38","author":"Agostinelli","year":"2010","journal-title":"Amino Acids"},{"key":"key20180108003410_b117-mmr-16-04-4393","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091534","article-title":"Silver nanoparticles: Synthesis, characterization, properties, applications, and therapeutic approaches (Review)","volume":"17","author":"Zhang","year":"2016","journal-title":"Int J Mol Sci"},{"key":"key20180108003410_b118-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1016\/j.biomaterials.2009.08.008","article-title":"Antiangiogenic properties of silver nanoparticles","volume":"30","author":"Gurunathan","year":"2009","journal-title":"Biomaterials"},{"key":"key20180108003410_b119-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcis.2013.11.040","article-title":"A review of the removal of anions and oxyanions of the halogen elements from aqueous solution by layered double hydroxides","volume":"417","author":"Theiss","year":"2014","journal-title":"J Colloid Interface Sci"},{"key":"key20180108003410_b120-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"1600229","DOI":"10.1002\/advs.201600229","article-title":"Anti-metastatic and anti-angiogenic activities of core-shell SiO2@LDH loaded with etoposide in non-small cell lung cancer","volume":"3","author":"Zhu","year":"2016","journal-title":"Adv Sci Weinh"},{"key":"key20180108003410_b121-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.actbio.2016.04.026","article-title":"Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy","volume":"38","author":"Banerjee","year":"2016","journal-title":"Acta Biomater"},{"key":"key20180108003410_b122-mmr-16-04-4393","first-page":"5464","article-title":"Pachymic acid modified carbon nanoparticles reduced angiogenesis via inhibition of MMP-3","volume":"8","author":"Ma","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"key20180108003410_b123-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bmcl.2013.11.045","article-title":"Inhibition effects of gold nanoparticles on proliferation and migration in hepatic carcinoma-conditioned HUVECs","volume":"24","author":"Pan","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180108003410_b124-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.molstruc.2009.02.004","article-title":"Study of protein-gold nanoparticle conjugates by fluorescence and surface-enhanced Raman scattering","volume":"924\u2013926","author":"Iosin","year":"2009","journal-title":"J Mol Struct"},{"key":"key20180108003410_b125-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"30619","DOI":"10.1038\/srep30619","article-title":"Gold Nanoparticle-mediated targeted delivery of recombinant human endostatin normalizes tumour vasculature and improves cancer therapy","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"key20180108003410_b126-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer (Review)","volume":"3","author":"Jain","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"key20180108003410_b127-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"key20180108003410_b128-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"key20180108003410_b129-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1158\/0008-5472.CAN-13-2986","article-title":"Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer","volume":"74","author":"Chatterjee","year":"2014","journal-title":"Cancer Res"},{"key":"key20180108003410_b130-mmr-16-04-4393","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3389\/fphar.2016.00519","article-title":"Anti-angiogenic therapy in cancer: Downsides and new pivots for precision medicine (Review)","volume":"7","author":"Lupo","year":"2017","journal-title":"Front Pharmacol"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T10:12:04Z","timestamp":1602670324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2017.7179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,7]]},"references-count":130,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,8,7]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.3892\/mmr.2017.7179"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2017.7179","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,7]]}}}